Phase 1 Study of Ruxolitinib, Steroids, and Lenalidomide to Treat Adults with Relapsed or Refractory Multiple Myeloma
Led by Oncotherapeutics · Updated on 2023-11-01
134
Participants Needed
13
Research Sites
126 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination therapy of ruxolitinib, steroids, and lenalidomide in adults with relapsed or refractory multiple myeloma MM who have progressive disease despite previous treatments. MM is a cancer of plasma cells in the bone marrow with complex causes and limited curative options. This phase 1, open-label, multicenter study aims to assess the safety and effectiveness of these drugs together in patients who have failed at least two prior therapies including immunomodulatory drugs and proteasome inhibitors.
Participants receive varying doses of ruxolitinib orally twice daily, lenalidomide once daily, and methylprednisolone every other day. The study includes dose escalation periods and treatment adjustments based on disease progression. Some groups start with ruxolitinib and steroids, adding lenalidomide only if the disease worsens. Treatment continues until disease progression or unacceptable side effects occur.
During the study, participants will have regular evaluations including blood tests and clinical assessments to monitor safety, side effects, and treatment response. Researchers will measure outcomes such as the maximum tolerated dose, adverse events, response rates, progression-free and overall survival over a follow-up period extending up to 54 months. Participants are expected to adhere to visit schedules and study requirements throughout the trial.
CONDITIONS
Brief Title
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Research Team
J
James R Berenson, MD
A
Afra Yehwalashet
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Current guideline-recommended RRMM therapy (external context)
What it is
An investigational, sequential regimen combining ruxolitinib (a JAK inhibitor), methylprednisolone (a corticosteroid), and, in certain cohorts, lenalidomide for adults with relapsed/refractory multiple myeloma who have progressed after prior therapies.
Recommended current standard therapies for relapsed/refractory multiple myeloma after IMID and proteasome inhibitor exposure often include combination regimens such as pomalidomide-dexamethasone, daratumumab-based combinations, carfilzomib-based regimens, or selinexor-dexamethasone, per consensus guidelines.
Role in trial or care
Studied as a new potential treatment approach for RRMM after multiple prior lines, including those refractory to other therapies; evaluated in sequential cohorts to establish safety and early efficacy.
Used as guideline-recommended systemic treatment for RRMM to control disease and improve outcomes after standard therapies are exhausted.
Primary use or purpose
To determine the maximum tolerated dose, safety, and initial response rate of ruxolitinib-based sequential regimens in heavily pre-treated RRMM.
To provide disease control, improve survival, and manage symptoms in patients with advanced or refractory MM after prior therapy, according to best available evidence.
How it is given or performed
Ruxolitinib and methylprednisolone are given orally in repeating cycles; lenalidomide is added in later cycles for some cohorts. Administration sequence and dose vary by cohort protocol.
Regimens are typically administered in cycles, e.g., pomalidomide and dexamethasone orally; daratumumab intravenously or subcutaneously plus backbone agents; specific regimens, dosing, and administration route depend on selected standard protocol and patient suitability.
Evidence status
Early-phase evidence from ongoing and published phase 1 trials shows tolerability and preliminary clinical activity, but the regimen remains investigational and comparative benefit over standard regimens is unknown.
Multiple large randomized controlled trials and meta-analyses support the efficacy of these regimens in improving response rates, progression-free survival, and symptom control for RRMM post-IMID/PI.
Important limitations
Findings are limited by phase 1 design, small sequential cohorts, heterogeneous patient backgrounds, and lack of randomization. Direct comparisons to frontline standard therapies are not available; only short-term efficacy and initial safety are reported. Regimen is not yet proven to improve survival.
Responses to guideline-based regimens may diminish with more lines of prior therapy. Toxicities such as cytopenias, infections, or infusion reactions can limit their use. Choice of therapy is guided by prior exposure and tolerance, so optimal regimen may differ by patient.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 years or older
Diagnosis of multiple myeloma confirmed by defined major and minor criteria including biopsy, bone marrow plasmacytosis, or monoclonal immunoglobulin levels
Measurable multiple myeloma disease by serum or urine protein levels or involved free light chain levels
Currently has progressive multiple myeloma
Relapsed or refractory after at least two prior therapies including an immunomodulatory drug and a proteasome inhibitor
Previous exposure to lenalidomide regardless of response
Not a candidate for transplant
Able to understand and voluntarily sign informed consent
Able to comply with study visit schedule and protocol
ECOG performance status of 2 or less
Life expectancy greater than 3 months
Laboratory test results within specified ranges for blood counts, kidney and liver function, and electrolytes
Registered with and able to comply with the REVLIMID REMS program
Female participants of childbearing potential must have negative pregnancy tests and agree to birth control requirements
Able to take aspirin or acceptable blood thinner if platelet count is sufficient
You will not qualify if you...
Diagnosis of POEMS syndrome
Plasma cell leukemia with high circulating plasma cells
Primary amyloidosis
Non-hematologic cancer within past 5 years except certain treated or low-risk cancers
Significant heart disease or impaired cardiac function
Severe hypercalcemia (serum calcium 12 mg/dL or higher)
Serious medical or psychiatric illness preventing informed consent
Any condition increasing risk or interfering with study interpretation
Major surgery within 28 days prior to enrollment or not recovered from surgery effects
Pregnant or breastfeeding females
Recent chemotherapy, corticosteroids, immunotherapy, or certain drug use within specified timeframes before study drugs
Known allergies to thalidomide, lenalidomide, or steroids
Concurrent use of other anti-cancer treatments
History of severe skin reaction while taking thalidomide or similar drugs
Known HIV, hepatitis B or C infection, or active/latent tuberculosis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Repeated 28-day cycles until disease progression or discontinuation
Participants receive treatment cycles including Ruxolitinib, Lenalidomide, and Methylprednisolone as prescribed to evaluate safety and efficacy for relapsed or refractory multiple myeloma.
1 visit per treatment cycle (in-person)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Evaluating 18F-Fluciclovine PETCT Imaging for Multiple Myeloma Detection and Monitoring
Evaluating 68Ga-BCMA PETCT Imaging for Detecting BCMA in Multiple Myeloma Patients in a Multicenter Study
Italian National Registry to Monitor Diagnosis and Treatment of Multiple Myeloma
A Physician and Patient-Powered Cohort Study
Evaluating BCMA-Targeted Prime CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma and Plasma Cell Disease
Phase 1 Study of Subcutaneous TQB2934 Injection for Treating Malignant Plasma Cell Tumors Including Multiple Myeloma
Study of Allogeneic CD19 and BCMA CAR-T Cell Therapy for Adults with Relapsed or Refractory B-cell or Plasma Cell Tumors
Early Phase 1 Trial to Assess Safety and Effectiveness of RN1101 Treatment
Phase I Open-Label Study of SHR-5421 Injection Evaluating Safety and Preliminary Effects in Patients With Multiple Myeloma
Phase I Study of SHR-9539 Injection to Evaluate Safety and Effectiveness in Adults With Multiple Myeloma
Phase 1 Study of TQB2029 Injection to Test Safety and Effects in Adults With Multiple Myeloma
Evaluating Safety and Effectiveness of LVIVO-TaVec200 in Adults with Relapsed or Refractory Multiple Myeloma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.